글로벌 호흡곤란 치료 시장 – 2028년까지의 산업 동향 및 예측

호흡곤란 치료 시장의 시장 분석 및 통찰력

Data Bridge Market Research는 호흡곤란 치료가 2021-2028년 예측 기간 동안 약 5.40%의 CAGR을 보일 것이라고 분석했습니다. 표적 치료 모드에 대한 수요 증가, 신약 및 치료법 개발을 위한 연구 개발 활동 급증, 호흡기 질환의 높은 유병률, 의료 인프라 개발에 대한 지출 증가가 호흡곤란 치료 시장 성장에 기여하는 주요 요인입니다.

호흡곤란은 호흡 시 불편한 감각을 느끼는 호흡기 질환입니다. 공기 허기 또는 호흡 곤란이라고도 알려진 호흡곤란은 화학 물질, 연기, 먼지, 연기와 같은 환경 오염 물질에 노출되어 발생합니다. 이 질환은 심장 질환을 앓고 있는 환자에게 흔합니다.

천식, 폐렴, 심근 허혈 및 기타 호흡기 질환의 전 세계적 유병률 증가는 시장 성장을 촉진하는 주요 요인입니다. 의료 인프라 개발에 대한 지출 증가, 실내 및 실외 오염 물질의 유병률 증가, 시장 참여자 간의 전략적 협력 비율의 급증은 시장 성장을 촉진하는 다른 요인입니다. 이 질병 치료에 대한 충족되지 않은 요구 증가와 더불어 개인의 가처분 소득 증가는 수익성 있는 시장 성장 기회를 창출할 또 다른 간접적인 결정 요인입니다.

그러나 사람들 사이의 인식 부족과 개발도상국과 저개발 경제권에서의 불리한 보상 시나리오는 시장 성장에 큰 도전이 될 것입니다. 또한, 연구 개발 능력과 관련된 높은 비용은 시장 성장률을 더욱 떨어뜨릴 것입니다. 치료와 관련된 높은 비용도 시장 성장률을 방해할 것입니다.

This dyspnea treatment market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on dyspnea treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Dyspnea Treatment Market Scope and Market Size

The dyspnea treatment market is segmented on the basis of treatment type, drugs, route of administration and end users. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

• On the basis of treatment type, the dyspnea treatment market is segmented into supplemental oxygen therapy and relaxation therapy.
• On the basis of drugs, the dyspnea treatment market is segmented into antianxiety, antibiotics, anticholinergic agents, corticosteroids and others. Antianxiety agents segment is sub-segmented into lorazepam and alprazolam. Antibiotics agent segment is sub-segmented into azithromycin and levofloxacin. Anticholinergic agents segment is sub-segmented into ipratropium bromide. Corticosteroids segment is sub-segmented into beclomethasone.
• On the basis of route of administration, the dyspnea treatment market is segmented into oral, inhalation and others.  
• On the basis of end users, the dyspnea treatment market is segmented into hospitals, home care, speciality clinics, ambulatory services and others.

Dyspnea Treatment Market Country Level Analysis

The dyspnea treatment market is analysed and market size insights and trends are provided by country, treatment type, drugs, route of administration and end users as referenced above.

The countries covered in the dyspnea treatment market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

North America dominates the dyspnea treatment market owing to the high prevalence of obesity and cardiopulmonary diseases and presence of major players in this region. Asia-Pacific is projected to score highest growth rate and exhibit the highest CAGR for the forecast period. This is because of the rising expenditure to develop healthcare infrastructure and growing prevalence of respiratory disorders.

The country section of the dyspnea treatment market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

The dyspnea treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Dyspnea Treatment Market Share Analysis

The dyspnea treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to dyspnea treatment market.

호흡곤란 치료 시장 보고서에 포함된 주요 기업으로는 Lannett, Teva Pharmaceutical Industries Ltd, GlaxoSmithKline plc, Bausch Health, Ligand Pharmaceuticals Incorporated, Jazz Pharmaceuticals, Inc., Hisamitsu Pharmaceutical Co., Inc., LANNETT, Amneal Pharmaceuticals LLC, Mylan NV, Lupin., AKRON, Inc., ANI Pharmaceuticals, Inc., Pfizer Inc., Novartis AG, Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Ltd, Aurobindo Pharma, Nephron Pharmaceuticals Corporation, Zydus Cadila 등이 있습니다. 시장 점유율 데이터는 글로벌, 북미, 유럽, 아시아 태평양(APAC), 중동 및 아프리카(MEA), 남미에 대해 각각 제공됩니다. DBMR 분석가는 경쟁 우위를 이해하고 각 경쟁자에 대한 경쟁 분석을 개별적으로 제공합니다.

SKU-48028